Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis

G Cheng, Q Zhang, J Pan, Y Lee, O Ouari… - Nature …, 2019 - nature.com
Lung cancer often has a poor prognosis, with brain metastases a major reason for mortality.
We modified lonidamine (LND), an antiglycolytic drug with limited efficacy, to mitochondria …

A novel autophagy/mitophagy inhibitor liensinine sensitizes breast cancer cells to chemotherapy through DNM1L-mediated mitochondrial fission

J Zhou, G Li, Y Zheng, HM Shen, X Hu, QL Ming… - Autophagy, 2015 - Taylor & Francis
Autophagy inhibition has been widely accepted as a promising therapeutic strategy in
cancer, while the lack of effective and specific autophagy inhibitors hinders its application …

Inhibition of mitochondrial complex II by the anticancer agent lonidamine

L Guo, AA Shestov, AJ Worth, K Nath… - Journal of Biological …, 2016 - ASBMB
The antitumor agent lonidamine (LND; 1-(2, 4-dichlorobenzyl)-1H-indazole-3-carboxylic
acid) is known to interfere with energy-yielding processes in cancer cells. However, the …

Targeting mitochondria for cancer therapy

S Fulda, L Galluzzi, G Kroemer - Nature reviews Drug discovery, 2010 - nature.com
Mitochondria are the cells' powerhouse, but also their suicidal weapon store. Dozens of
lethal signal transduction pathways converge on mitochondria to cause the permeabilization …

Mitochondrial-targeting lonidamine-doxorubicin nanoparticles for synergistic chemotherapy to conquer drug resistance

Y Liu, X Zhang, M Zhou, X Nan, X Chen… - ACS applied materials …, 2017 - ACS Publications
Lonidamine (LND) can act on mitochondria and inhibit energy metabolism in cancer cells
and therefore has been used together with chemotherapy drugs for synergistically enhanced …

Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore

L Ravagnan, I Marzo, P Costantini, SA Susin… - Oncogene, 1999 - nature.com
The molecular mode of action of lonidamine, a therapeutic agent employed in cancer
chemotherapy, has been elusive. Here we provide evidence that lonidamine (LND) acts on …

The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters

B Nancolas, L Guo, R Zhou, K Nath… - Biochemical …, 2016 - portlandpress.com
Lonidamine (LND) is an anti-tumour drug particularly effective at selectively sensitizing
tumours to chemotherapy, hyperthermia and radiotherapy, although its precise mode of …

Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism

AM Strohecker, E White - Autophagy, 2014 - Taylor & Francis
The role of autophagy in cancer is complex and context-dependent. Here we describe work
with genetically engineered mouse models of non-small cell lung cancer (NSCLC) in which …

Targeting cancer cell mitochondria as a therapeutic approach: recent updates

Q Cui, S Wen, P Huang - Future Medicinal Chemistry, 2017 - Taylor & Francis
Mitochondria play a key role in ATP generation, redox homeostasis and regulation of
apoptosis. Due to the essential role of mitochondria in metabolism and cell survival …

Treatment strategies that enhance the efficacy and selectivity of mitochondria-targeted anticancer agents

JS Modica-Napolitano, V Weissig - International journal of molecular …, 2015 - mdpi.com
Nearly a century has passed since Otto Warburg first observed high rates of aerobic
glycolysis in a variety of tumor cell types and suggested that this phenomenon might be due …